Treatment outcome of the EXTREME regimen as first-line therapy and nivolumab as second-line or third-line therapy for recurrent/metastatic head and neck squamous cell carcinoma in a multiple-center study
Treatment outcome of the EXTREME regimen as first-line therapy and nivolumab as second-line or third-line therapy for recurrent/metastatic head and neck squamous cell carcinoma in a multiple-center study
复制标题
多中心研究中 EXTREME 方案作为一线治疗和纳武单抗作为二线或三线治疗复发/转移性头颈鳞状细胞癌的治疗结果
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Oridate N
中科院分区：
文献类型：
--
作者：
Sano D;Tokuhisa M;Ichikawa Y;Oridate N
